COVID-19 Vaccination
Conditions
Interventions
Group 1: Booster immunization against SARS-CoV-2
Sponsors
Max Planck-Institut
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Participants were adults 18-40 years of age, with no underlying health conditions, belonging to the Robert Koch priority group 4. Participants must intend to be vaccinated against COVID-19 and be able to receive their vaccination during the study timeline (~Sept 2021-Dec 2022). Any of the COVID-19 vaccinations approved by the Robert Koch Institute at the time of study participation (e.g., BioNTech/Pfizer, Moderna, Johnson & Johnson or other commercially available vaccines) will be permitted for inclusion in the study, including booster shots. Participants must be able to read and understand German or English to provide informed consent for themselves.
Exclusion criteria
Exclusion criteria: Exclusion criteria include known gastrointestinal disorders (e.g., Inflammatory Bowel Disease or Celiac Disease), recent antibiotics use (any antibiotics taken in the three months prior to study participation), and pregnancy. Any health factor which places someone at higher risk of COVID-19 disease, and therefore in a higher vaccine priority group (1-3) according to the Robert Koch Institute will also be excluded. These exclusion risk factors, as listed by the Robert Koch Institute, include diabetes mellitus, obesity (BMI>30), asthma, autoimmune diseases, neurological diseases, cancer, and diseases of the lung, heart, liver, or kidney. Immunocompromised and immunosuppressed people are also explicitly excluded. However, healthy individuals who receive vaccine prioritization for occupational reasons (for example, researchers working at the hospital campus) are not excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interplay of the intestinal microbiome and fever and antibody responses to SARS-CoV-2 vaccination | — |
Secondary
| Measure | Time frame |
|---|---|
| Temporal responsiveness of the intestinal microbiome to immunisation against SARS-CoV-2 | — |
Countries
Germany
Contacts
Public ContactRuth Ley
Max Planck Institute for Biology
Outcome results
None listed